HUTCHMED (China) stock
HCMNASDAQHUTCHMED (China) Limited, HealthcareISIN US44842L1035
45Score 45 out of 100, Weak
Price and trend
86 / 100
Price history
−1.0% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 6.0% below its 52-week high. Largest decline in 11 years: 82% (August 2021 to October 2022).
Chart figures for advanced users
- SMA 50$13.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.99
- The lowest closing price of the last twelve months.
- Resistance$16.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- HUTCHMED (China) Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (Hong Kong SAR China) and, with a market value of $2.63B, is number 48 of 78 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $549.96M (down 12.7% year on year) and earnings of $458.12M (up 1,114.2%).
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 465 of 714 in Healthcare, median 53.
- The P/E is 147.2 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 47.8).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $1.38B, financial debt $94.51M.Stability 61
- Growing faster than its industryRevenue up 19.2% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 66
Weaknesses
- Richly valuedP/E 147.2, Drug Manufacturers (Specialty & Generic) median 19.3, own median 47.8.Valuation 10
Its standout strengths are technical analysis and momentum, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 45.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
OvervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 8.8% on the twelve months before. Revenue has grown strongly since 2012, at around 28% per year. From 2012 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2012 are not measured.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 39%, operating −10%, net 83%. Last 12 months: net 3%. From 2012 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2012 are not measured.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 112 days
- Last reported
- 30 Jul 2026below expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 3.1% since 15 Oct 2026.
- Earnings per share
- 0.36+3.1%
- Revenue
- $625.17M0.0%
- Earnings per share
- 0.46+0.3%
- Revenue
- $705.43M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at HUTCHMED (China)
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Laboratorios Farmaceuticos RoviROVI.MC $4.02B82
- Siegfried HoldingSFZN.SW $3.77B55
- Bausch Health CompaniesBHC $3.13B61
- Regencell Bioscience HoldingsRGC $2.68B31
- AlmirallALM.MC $2.61B45
- PerrigoPRGO $2.3B48
- Trulieve CannabisTRLV $2.17B48
- Dermapharm HoldingDMP.DE $2.13B68
ETFs that hold HUTCHMED (China)
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR MSCI Emerging Markets Small Cap UCITS ETFSPYX | 0.12% | 0.55% | €516.44M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.